CONFIDENTIAL



                   MassARRAY(TM) Distribution Contract Terms





                          SEQUENOM, Inc ("Sequenom")



                                      and



                   Nissei Sangyo Co., Ltd. ("Nissei Sangyo")





     Between, Nissei Sangyo Co., Ltd., ("Nissei Sangyo") a corporation duly

organized and existing under the laws of Japan having offices at 24-14, Nishi-

shimbashi, 1-chome, Minato-ku, Tokyo, 105-8717 Japan and Sequenom, Inc.

("Sequenom") a Delaware corporation having its principal place of business at

11555 Sorrento Valley Road, San Diego, California 92121-1331, U.S.A.

(collectively the "parties"); and



     Whereas, Sequenom is in the business of, among other things, designing,

developing, manufacturing and selling proprietary biopolymer analysis products

and related software and consumables; and



     Whereas, Sequenom has expertise in the development and utilization of mass

spectrometry for biopolymer analysis and has developed Sequenom's proprietary

MassARRAY(TM) products for high-throughput DNA analysis;



     Whereas, Nissei Sangyo and Sequenom desire to enter into a relationship

pursuant to which Sequenom will grant Nissei Sangyo certain rights to distribute

Sequenom's MassARRAY products and consumables throughout Japan and Nissei Sangyo

will actively market, sell, and service such products throughout Japan.



     Whereas, Sequenom and Nissei Sangyo would like to set forth the general

terms and conditions of such an arrangement in this binding Letter of Intent,

which upon execution, obligates the parties as follows:





1. General Terms



1.1  Exclusivity: Nissei Sangyo will act as Sequenom's exclusive distributor of

     MassARRAY systems, software and consumables in the Territory.



1.2  Field of Use: Sequenom grants Nissei Sangyo the right to sub-license

     MassARRAY technology for the field of individual DNA genotyping in the

     Territory under the condition that each new MassARRAY customer in the

     Territory shall sign a separate sub-licensing agreement consistent with the

     terms set forth in the distribution agreement.



     1.2.1  Sequenom grants Nissei Sangyo the right to sub-license MassARRAY to

            parties in the Territory for internal R&D purposes without

            additional

{PAGE}



            Sequenom consent provided that the party executes an R&D sub-

            licensing agreement.



     1.2.2  Sequenom grants Nissei Sangyo the right to sub-license MassARRAY to

            parties in the Territory for commercial purposes but only with

            Sequenom's prior written consent and provided that the party

            executes a commercial sub-licensing agreement. Such commercial

            sublicensing agreement will provide for royalty payments to Nissei

            Sangyo for such commercial use, with a portion thereof to be paid by

            Nissei Sangyo to Sequenom.



1.3  Territory: Territory for the contract is Japan.



1.4  Term: [...***...].



     1.4.1  Termination date is [...***...].



     1.4.2  Renewable on an annual basis thereafter upon mutual agreement.



1.5  Products: All new assays, instruments and software products that are

     commercially available for distribution will be made available for Nissei

     Sangyo to sell in the Japanese market for the duration of the Distribution

     Contract.



     1.5.1  Sequenom will provide a protocol and components for a commercial

            homogeneous MassEXTEND assay (hME) to Nissei Sangyo for sale in the

            Territory as soon as it is a commercially available product

            (estimated commercial release: by the end of 2000).



     1.5.2  Nissei Sangyo will have access to Sequenom developed genotyping

            assay panels (however, not including specific diagnostic panels) at

            a standard distribution transfer price, and the right to sell such

            assay panels in the Territory when they are commercially released

            for customer use.



     1.5.3  The Distribution Contract does not provide Nissei Sangyo with the

            right to sell or make use of Sequenom's proprietary technology for

            rapid Allele Frequency Determination by Pooling. The sale or support

            of genotyping programs within the Territory that would make use of

            this Pooling technology will require completion of a separate and

            independent agreement. Also, Nissei Sangyo will only have the right

            to sell Sequenom diagnostic panels on a non-exclusive basis and

            under licensing and royalty conditions defined in a separate

            diagnostic assay licensing and royalty agreement. The term

            commercial diagnostic service applies to the provision of a

            commercial service providing medical diagnostic information to a

            patient or to an intermediate company/provider that would then

Home        Intelligence        Services        Subscriptions        News        About Us

Contact Us       Terms of Use       Resend Documents       Shopping Cart

Copyright © 2008 The Consus Group LLC